Raymond James downgraded shares of Gossamer Bio (NASDAQ:GOSS – Get Rating) from an outperform rating to a market perform rating in a report published on Tuesday morning, The Fly reports.
GOSS has been the subject of several other research reports. Sumitomo Mitsui Financial Group cut shares of Gossamer Bio from an outperform rating to a neutral rating and set a $3.00 price target for the company. in a report on Wednesday, December 7th. HC Wainwright lowered their price target on shares of Gossamer Bio from $25.00 to $5.00 and set a buy rating for the company in a report on Thursday, December 8th. The Goldman Sachs Group reduced their price objective on shares of Gossamer Bio from $22.00 to $10.00 and set a buy rating for the company in a research report on Wednesday, December 7th. Evercore ISI reduced their price objective on shares of Gossamer Bio to $7.00 in a research report on Monday, December 12th. Finally, UBS Group reduced their price objective on shares of Gossamer Bio from $19.00 to $8.00 and set a buy rating for the company in a research report on Wednesday, December 7th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of Hold and a consensus target price of $10.25.
Gossamer Bio Price Performance
Gossamer Bio stock opened at $1.67 on Tuesday. The company has a debt-to-equity ratio of 3.73, a quick ratio of 5.93 and a current ratio of 5.93. The company has a market capitalization of $157.78 million, a price-to-earnings ratio of -0.58 and a beta of 1.25. The company’s 50 day simple moving average is $2.19 and its 200-day simple moving average is $7.32. Gossamer Bio has a 1 year low of $1.57 and a 1 year high of $15.20.
Institutional Trading of Gossamer Bio
About Gossamer Bio
Gossamer Bio, Inc engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions.
- Get a free copy of the StockNews.com research report on Gossamer Bio (GOSS)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.